IRLAB has Activated all 38 Study Sites in the Phase IIb Study of Pirepemat Aiming to Improve Balance and Reduce Falls in Parkinson’s Disease

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that all participating study sites in the Phase IIb study of pirepemat are activated and recruiting patients.